3-O-Decyclopropyl Roflumilast

For research use only. Not for therapeutic Use.

  • CAT Number: R056993
  • CAS Number: 1391052-76-8
  • Molecular Formula: C13H8Cl2F2N2O3
  • Molecular Weight: 349.115
  • Purity: ≥95%
Inquiry Now

3-O-Decyclopropyl Roflumilast (CAS&nbsp;1391052-76-8) is the<span style="color: rgb(17, 17, 17); font-family: Roboto, Helvetica, Tahoma, Arial, sans-serif, SimSun; font-variant-ligatures: normal; orphans: 2; widows: 2;">&nbsp;impurity of Roflumilast, which is a selective and long-acting inhibitor of PDE-4 with IC50 value of 0.8 nM.&nbsp;</span><span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;"><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">Due to its selective inhibition of the PDE4 isoenzyme in lung cells, roflumilast is indicated for the management of chronic obstrtuctive pulmonary disease (COPD) exacerbations.</span></span></span>


Catalog Number R056993
CAS Number 1391052-76-8
Synonyms

3-(Hydroxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide;

Molecular Formula C13H8Cl2F2N2O3
Purity ≥95%
Target Phosphodiesterase (PDE)
Storage -20°C
IUPAC Name N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxybenzamide
InChI InChI=1S/C13H8Cl2F2N2O3/c14-7-4-18-5-8(15)11(7)19-12(21)6-1-2-10(9(20)3-6)22-13(16)17/h1-5,13,20H,(H,18,19,21)
InChIKey GZHTYXYJBZYTEV-UHFFFAOYSA-N
SMILES C1=CC(=C(C=C1C(=O)NC2=C(C=NC=C2Cl)Cl)O)OC(F)F
Reference

<p>
<span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;"><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">1.Calverley, Peter MA, et al. &quot;Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.&quot;&nbsp;</span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">American journal of respiratory and critical care medicine</i><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">&nbsp;176.2 (2007): 154-161.<br />
2.</span><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">Calverley, Peter MA, et al. &quot;Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.&quot;&nbsp;</span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">The Lancet</i><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">&nbsp;374.9691 (2009): 685-694.<br />
3.</span><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">Fabbri, Leonardo M., et al. &quot;Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.&quot;&nbsp;</span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">The Lancet</i><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">&nbsp;374.9691 (2009): 695-703.</span></span></span></p>

Request a Quote